ZYVERSA THERAPEUTICS, INC. Accounts Payable
ZYVERSA THERAPEUTICS, INC. (ZVSA) had Accounts Payable of $10.24 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-05-13
- 2026-03-31: Accounts Payable, Current $10.24M.
- 2025-12-31: Accounts Payable, Current $10.12M.
- 2025-09-30: Accounts Payable, Current $9.81M.
- 2025-06-30: Accounts Payable, Current $9.77M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-03-31 | $10.24M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $10.12M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $9.81M 10-Q · filed 2025-11-19 |
| 2025-06-30 | $9.77M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $9.60M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $9.34M 10-K · filed 2026-03-31 |
| 2024-09-30 | $9.28M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $8.32M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $8.13M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $8.43M 10-K · filed 2025-03-27 |
| 2023-09-30 | $8.90M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $8.14M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $6.38M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $6.03M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |